Rgnia Dermaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 24 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.36 Cr
- Revenue Growth 39.42%
- Profit Growth 100.78%
- Ebitda 79.00%
- Net Worth 103.48%
- Total Assets 11.30%
About Rgnia Dermaceuticals
Rgnia Dermaceuticals Private Limited (RDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 January 2007 and has a history of 18 years. Its registered office is in Delhi, India.
The Corporate was formerly known as Ashmon Infotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.36 Cr.
Anuragini Gupta and Ram Gupta serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100DL2007PTC157576
-
Company No.
157576
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jan 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Rgnia Dermaceuticals?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Anuragini Gupta | Director | 12-May-2014 | Current |
Ram Gupta | Director | 06-Feb-2014 | Current |
Financial Performance of Rgnia Dermaceuticals.
Rgnia Dermaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.42% increase. The company also saw a substantial improvement in profitability, with a 100.78% increase in profit. The company's net worth Soared by an impressive increase of 103.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Rgnia Dermaceuticals?
Unlock access to Rgnia Dermaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹53.64 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 5.30 Cr
- Hdfc Bank Limited : 0.06 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
22 Oct 2022 | Axis Bank Limited | ₹1.80 Cr | Open |
04 May 2022 | Hdfc Bank Limited | ₹0.64 M | Open |
29 May 2020 | Axis Bank Limited | ₹3.50 Cr | Open |
How Many Employees Work at Rgnia Dermaceuticals?
Unlock and access historical data on people associated with Rgnia Dermaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rgnia Dermaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rgnia Dermaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.